Jeffrey Lancet, MD, discusses the findings from a phase III trial of CPX-351 versus 7+3 in older patients with high-risk, secondary acute myeloid leukemia
CPX-351: A Potential Game-Changer for Older Patients With Newly Diagnosed Secondary AML?
Recent Articles
Is there a genetic risk for familial CLL?
This month, Kanti R. Rai, MD, discusses familial chronic lymphocytic leukemia.
And don't forget to check out next month's clinical dilemma - send in your...
Venetoclax Plus Obinutuzumab Confers High MRD-Negative Rates in CLL
Results from a phase Ib study demonstrated that the combination of the BCL2 inhibitor venetoclax with the anti-CD20 monoclonal antibody obinutuzumab was safe and...
Remembering Arthur Rosenberg, Dorothy Tuan Lo, and more
Remembering Arthur Rosenberg (1935 – 2018)
Arthur Rosenberg, MD, FRCPC, a former chief of hematology at the Jewish General Hospital (JGH) in Montreal, Quebec, passed...
Pulling Back the Curtain: Clara Bloomfield, MD
In this edition, Clara Bloomfield, MD, talks about being on the right project at the right time and having academia in her blood.Where did...
Raising the Barre: Kimberly Stegmaier, MD
In this edition, Kimberly Stegmaier, MD, discusses her passion for ballet.What was your first experience with ballet?
I grew up in Long Island and my...
Current Issue
April 2019, Volume 5, Issue 5
This issue features a look at the pitfalls of presenting and interpreting clinical trial data, the latest advances in transplant presented at the 2019 TCT Meetings, and more.
